Davies J C, Geddes D M, Alton E W
Ion Transport Unit, Imperial College, National Heart and Lung Institute, London, UK.
Mol Med Today. 1998 Jul;4(7):292-9. doi: 10.1016/s1357-4310(98)01265-9.
Despite advances in conventional treatments for cystic fibrosis (CF), the disease is still associated with significant morbidity and mortality. The cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and the understanding of the functions of the CFTR protein have led to the development of novel treatment strategies, including gene therapy. Here, we review the underlying molecular defect in CF cells, and the progress in gene-transfer studies from in vitro work through to clinical trials. We discuss the problems encountered, the end-points used to assess efficacy, and the likely future directions of the field.
尽管囊性纤维化(CF)的传统治疗方法取得了进展,但该疾病仍与显著的发病率和死亡率相关。囊性纤维化跨膜传导调节因子(CFTR)基因的克隆以及对CFTR蛋白功能的了解促使了包括基因治疗在内的新型治疗策略的发展。在此,我们综述CF细胞潜在的分子缺陷,以及从体外研究到临床试验的基因转移研究进展。我们讨论了遇到的问题、用于评估疗效的终点指标以及该领域未来可能的发展方向。